What are the main functions of Pemetinib tablets and which patients are they suitable for?

Pemigatinib (Pemigatinib) is an oral small molecule targeted drug that mainly acts on the fibroblast growth factor receptor (FGFR) pathway. FGFR is a type of receptor tyrosine kinase closely related to cell proliferation, differentiation and survival. Abnormal changes in the FGFR gene in certain tumor cells, such as gene fusion, amplification or mutation, lead to abnormal activation of signaling pathways and promote tumor growth and metastasis. Pemetinib exerts anti-tumor effects by selectively inhibiting FGFR1, FGFR2 and FGFR3, blocking abnormal signal transduction and inhibiting the proliferation of tumor cells.

Pemetinib is mainly suitable for patients with cholangiocarcinoma carryingFGFR2 fusion or rearrangement. Cholangiocarcinoma is a malignant tumor originating from the bile duct epithelium. Traditional treatments have limited effects and poor prognosis. Studies have found that the tumor cells of some patients with cholangiocarcinoma have FGFR2 gene rearrangements, and the use of pemetinib can significantly improve the treatment effect of these patients. Pemetinib can delay tumor progression, improve patients' progression-free survival and overall survival rate, and provides an effective targeted treatment option for patients with cholangiocarcinoma carrying FGFR2 gene abnormalities.

In addition, pemetinib has also shown potential efficacy in other solid tumors carrying FGFR gene abnormalities, such as bladder cancer, non-small cell lung cancer, etc. However, its main approved indications are still concentrated in cholangiocarcinoma with FGFR2 fusion. Before treatment, molecular testing is required to determine whether the patient has FGFR2 fusion or rearrangement to accurately match targeted drugs and avoid ineffective treatment. Accurate detection and personalized medication are key links to ensure the therapeutic effect of pemetinib.

In general, pemetinib, as a new type of FGFR inhibitor, is suitable for patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement. It can effectively inhibit tumor cell proliferation and metastasis and prolong patient survival. With the development of precision medicine, pemetinib is expected to expand the therapeutic applications of more FGFR-related tumors in the future, bringing new treatment hope to more patients.

Reference materials:https://go.drugbank.com/drugs/DB15102